Scopus
🔓 Açık Erişim YÖKSİS DOI Eşleşti
SJR Q1
Management of patients with chronic rhinosinusitis during the COVID-19 pandemic—An EAACI position paper
Allergy European Journal of Allergy and Clinical Immunology · Mart 2021
YÖKSİS Kayıtları
Management of patients with chronic rhinosinusitis during the COVID\u201019 pandemic\u2014An EAACI position paper
Allergy · 2021 SSCI
Prof. Dr. BANU BOZKURT →
YÖKSİS Kayıtları — ISSN Eşleşmesi
ILC3 deficiency and generalized ILC abnormalities in DOCK8‐deficient patients
2019 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU
2019 ISSN: 0105-4538 SCI
Doç. Dr. KEMAL EROL →
Management of patients with chronic rhinosinusitis during the COVID\u201019 pandemic\u2014An EAACI position paper
2021 ISSN: 0105-4538 SSCI Q1
Prof. Dr. BANU BOZKURT →
Development and preclinical evaluation of virus\u2010like particle vaccine against COVID\u201019 infection
2021 ISSN: 0105-4538 SCI-Expanded
Prof. Dr. OSMAN ERGANİŞ →
Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
2022 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Makale Bilgileri
ISSN01054538
Yayın TarihiMart 2021
Cilt / Sayfa76 · 677-688
Scopus ID2-s2.0-85096858440
Erişim🔓 Açık Erişim
Özet
Background: Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes. Methods: The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. Results: Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic. Conclusion: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.
Yazarlar (22)
1
Ludger Klimek
ORCID: 0000-0002-2455-0192
2
Marek Jutel
ORCID: 0000-0003-1555-9379
3
Jean Bousquet
4
Ioana Agache
ORCID: 0000-0001-7994-364X
5
Cezmi A. Akdis
ORCID: 0000-0001-8020-019X
6
Valerie Hox
ORCID: 0000-0003-2390-294X
7
Philippe Gevaert
ORCID: 0000-0002-1629-8468
8
Peter Valentin Tomazic
ORCID: 0000-0001-6445-4800
9
Carmen Rondon
ORCID: 0000-0003-0976-3402
10
Cemal Cingi
ORCID: 0000-0003-3934-5092
11
Sanna Toppila-Salmi
ORCID: 0000-0003-0890-6686
12
Aspasia Karavelia
13
Banu Bozkurt
ORCID: 0000-0002-9847-3521
14
Ulrike Förster-Ruhrmann
ORCID: 0000-0001-5059-5610
15
Sven Becker
16
Adam M. Chaker
ORCID: 0000-0002-5117-4073
17
Barbara Wollenberg
ORCID: 0000-0002-3062-459X
18
Ralph Mösges
ORCID: 0000-0002-1928-810X
19
Tilman Huppertz
ORCID: 0000-0003-0654-3551
20
Jan Hagemann
ORCID: 0000-0002-9846-7850
21
Claus Bachert
ORCID: 0000-0003-4742-1665
22
Wytske Fokkens
ORCID: 0000-0003-4852-229X
Anahtar Kelimeler
biologics
chronic rhinosinusitis
COVID-19
CRSwNP
SARS-CoV-2
Kurumlar
Amsterdam UMC - University of Amsterdam
Amsterdam Netherlands
Berliner Institut für Gesundheitsforschung
Berlin Germany
Center for Rhinology and Allergy
Wiesbaden Germany
Centre Hospitalier Universitaire de Montpellier
Montpellier France
Charité – Universitätsmedizin Berlin
Berlin Germany
Cliniques Universitaires Saint-Luc
Brussels Belgium
Eskişehir Osmangazi Üniversitesi
Eskisehir Turkey
European Academy of Allergy and Clinical Immunology (EAACI)
Zurich Switzerland
General Hospital of Chania
Chania Greece
Hospital Regional Universitario Carlos Haya
Malaga Spain
Karolinska Institutet
Stockholm Sweden
Karolinska Universitetssjukhuset
Stockholm Sweden
MACVIA-France
Montpellier France
Medizinische Universität Graz
Graz Austria
Selçuk Tip Fakültesi
Konya Turkey
Skin and Allergy Hospital
Helsinki Finland
Sun Yat-Sen University
Guangzhou China
TUM Fakultät für Medizin
Munich Germany
Uniklinik Köln
Koln Germany
Universitair Ziekenhuis Gent
Ghent Belgium
Universitatea Transilvania din Brașov
Brasov Romania
Universitätsklinikum und Medizinische Fakultät Tübingen
Tubingen Germany
Universität Zürich
Zurich Switzerland
Universiteit Gent
Ghent Belgium
University Medical Center
Mainz Germany
Wroclaw Medical University
Wroclaw Poland
Scimago Dergi (ISSN Eşleşmesi)
Allergy: European Journal of Allergy and Clinical Immunology
Q1
SJR Skoru3,851
H-Index226
YayıncıWiley-Blackwell Publishing Ltd
ÜlkeUnited Kingdom
Immunology (Q1)
Immunology and Allergy (Q1)
Metrikler
37
Atıf
22
Yazar
5
Anahtar Kelime